The ectonucleotidases CD39 and CD73 on T cells: The new pillar of hematological malignancy

Hematological malignancy develops and applies various mechanisms to induce immune escape, in part through an immunosuppressive microenvironment. Adenosine is an immunosuppressive metabolite produced at high levels within the tumor microenvironment (TME). Adenosine signaling through the A receptor ex...

Full description

Saved in:
Bibliographic Details
Published in:Frontiers in immunology 2023-01, Vol.14, p.1110325-1110325
Main Authors: Jiang, Xuan, Wu, Xiaofang, Xiao, Yuxi, Wang, Penglin, Zheng, Jiamian, Wu, Xiuli, Jin, Zhenyi
Format: Article
Language:English
Subjects:
5'-Nucleotidase - metabolism
Adenosine - metabolism
Adenosine Monophosphate - metabolism
CD39
CD73
Hematologic Neoplasms
hematological malignancy
Humans
Immunology
Immunosuppressive Agents
immunotherapy
T cells
T-Lymphocytes - metabolism
Tumor Microenvironment
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Hematological malignancy develops and applies various mechanisms to induce immune escape, in part through an immunosuppressive microenvironment. Adenosine is an immunosuppressive metabolite produced at high levels within the tumor microenvironment (TME). Adenosine signaling through the A receptor expressed on immune cells, such as T cells, potently dampens immune responses. Extracellular adenosine generated by ectonucleoside triphosphate diphosphohydrolase-1 (CD39) and ecto-5'-nucleotidase (CD73) molecules is a newly recognized 'immune checkpoint mediator' and leads to the identification of immunosuppressive adenosine as an essential regulator in hematological malignancies. In this Review, we provide an overview of the detailed distribution and function of CD39 and CD73 ectoenzymes in the TME and the effects of CD39 and CD73 inhibition on preclinical hematological malignancy data, which provides insights into the potential clinical applications for immunotherapy.
ISSN:1664-3224
1664-3224
DOI:10.3389/fimmu.2023.1110325